TOP > 外国特許検索 > β-MODIFIED PHOSPHORIC ACID COMPOUND PRECURSOR, β-MODIFIED PHOSPHORIC ACID COMPOUND, REACTION INHIBITOR, AND MEDICINE INCLUDING SAME, AND REACTION INHIBITION METHOD

β-MODIFIED PHOSPHORIC ACID COMPOUND PRECURSOR, β-MODIFIED PHOSPHORIC ACID COMPOUND, REACTION INHIBITOR, AND MEDICINE INCLUDING SAME, AND REACTION INHIBITION METHOD NEW

外国特許コード F200010027
整理番号 J1036-01WO
掲載日 2020年1月30日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2019JP009213
国際公開番号 WO 2019172394
国際出願日 平成31年3月8日(2019.3.8)
国際公開日 令和元年9月12日(2019.9.12)
優先権データ
  • 特願2018-043329 (2018.3.9) JP
発明の名称 (英語) β-MODIFIED PHOSPHORIC ACID COMPOUND PRECURSOR, β-MODIFIED PHOSPHORIC ACID COMPOUND, REACTION INHIBITOR, AND MEDICINE INCLUDING SAME, AND REACTION INHIBITION METHOD NEW
発明の概要(英語) A β-modified phosphoric acid compound precursor having the partial structure represented by formula 1A in the molecule thereof. A medicine and a reaction inhibitor containing the β-modified phosphoric acid compound precursor. (In the formula: A1 represents -SR1, -S-S-R1, -SeR1, or -X (where X is a halogen selected from fluorine, chlorine, bromine, and iodine), and R1 is hydrogen, a C1-20 alkyl group, or the like; L1 represents hydrogen, a C1-20 alkyl group, or the like, and L2 represents a C1-20 alkyl group or the like; L1 and L2 may be bonded to each other to form a 4 to 6-membered ring structure; L1 and L2 each may have a substituent; and * is a bond which is phosphorylated to bond to a phosphate group.)
従来技術、競合技術の概要(英語) BACKGROUND ART
Phosphorylation, important biological reactions and processes, a variety of in vivo phosphorylation reaction is performed. For example, in the replication of DNA, DNA polymerase DNA phosphorylation reaction is performed. DNA polymerase, primer sequences as a starting point, single-stranded DNA as a template that is complementary to the four deoxynucleotide triphosphates (dNTP) to the 3 'end can be associated in series, 3'→5 ' extending in the direction of the complementary strand DNA. In the reactions, DNA polymerase, dNTP three phosphoric acid phosphoric acid group is one of the 2 phosphorylated one phosphate group 1 and remains in the 3' terminus of the hydroxyl group at position 3 of the sugar (deokirishibosu) (hydroxyl group) binding. As a result, 3' phosphorylated saccharide may end, extension of the complementary strand DNA. Polymerase, DNA replication and transcription and involved in, such as cancer or viral diseases caused by the therapeutic agent may be an important factor in the target protein.
Also, mevalonate, terpenoid or compound involved in the synthesis of steroid. Mevalonate, the mevalonate kinase ATP as a substrate phosphorylated by 5-and with a nucleic acid, such as cholesterol are converted by the subsequent processes. Mevalonate, an important therapeutic agents such as hyperlipidemia also known as a target material.
In this way, in reaction to the phosphorylation is an important, and the subsequent reaction can be inhibited efficiently specifically, to provide a method for the treatment of various diseases can be potentially possible. However, in the prior art, due to the phosphorylation reaction selectively and efficiently inhibiting the biological reaction is insufficient.
For example, Patent Document 1 is, as an inhibitor of DNA polymerase acyclovir is disclosed. Acyclovir, phosphorylation and one of the virus in the host (the human) three phosphorylation, DNA polymerase reaction, of the stretch 3' may be coupled to a terminal side, viral DNA polymerase to onsisting.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
  • 発明者(英語)
  • ABE,Hiroshi
  • KIMURA Yasuaki
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close